Efficacy, Patient-Reported Outcomes (PROs), and Tolerability of the Changing Therapeutic Landscape in Patients with Metastatic Prostate Cancer (MPC): A Systematic Literature Review-Reference-Cited by-同舟云学术

Efficacy, Patient-Reported Outcomes (PROs), and Tolerability of the Changing Therapeutic Landscape in Patients with Metastatic Prostate Cancer (MPC): A Systematic Literature Review

Published:2013-07 Issue:5 Volume:16 Page:872-890
ISSN:1098-3015
Container-title:Value in Health
language:en
Short-container-title:Value in Health

Author:

Seal Brian S.,Asche Carl V.,Puto Katarzyna,Allen Pamela D.

Publisher

Elsevier BV

Subject

Public Health, Environmental and Occupational Health,Health Policy

Reference78 articles.

1. Cancer statistics, 2013;Siegel;CA Cancer J Clin,2013

2. Howlader N, Noone AM, Krapcho M, eds. SEER Cancer Statistics Review, 1975–2008. Bethesda, MD: National Cancer Institute, 2011. Available from: http://seer.cancer.gov/csr/1975_2008/ based on November 2010 SEER data submission, posted to the SEER Web site, 2011 [Accessed March 11, 2013].

3. New options for the management of castration-resistant prostate: a case perspective;Goetz;J Natl Compr Canc Netw,2011

4. Optimal hormone therapy for advanced prostatic carcinoma;Goktas;Semin Oncol,1999

5. National Comprehensive Cancer Network (NCCN) Practice Guidelines in OncologyTM. Available from: http://www.nccn.org. [Accessed April 7, 2012].

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Current attitudes of Canadian urologists towards surgical castration in the treatment of prostate cancer;Canadian Urological Association Journal;2020-10-27

2. Results From a Large, Multicenter, Retrospective Analysis On Radium223 Use in Metastatic Castration-resistant Prostate Cancer (mCRPC) in the Triveneto Italian Region;Clinical Genitourinary Cancer;2019-02

3. Treatments for Metastatic Prostate Cancer (mPC): A Review of Costing Evidence;PharmacoEconomics;2017-07-29

4. Impact of abiraterone on patient-related outcomes in metastatic castration-resistant prostate cancer: current perspectives;Cancer Management and Research;2017-07

5. First-line non-cytotoxic therapy in chemotherapy-naive patients with metastatic castration-resistant prostate cancer: a systematic review of 10 randomised clinical trials;BJU International;2017-02-28